US5641753AExpiredUtility

10-AZA-9-deoxo-11-deoxy-erythromycin A and derivatives combined with sulfisoxazole

Individually held — no corporate assignee on recordPriority: Mar 25, 1996Filed: Mar 25, 1996Granted: Jun 24, 1997
Est. expiryMar 25, 2016(expired)· nominal 20-yr term from priority
Inventors:Chris Platt
A61K 31/70C07H 17/08
31
PatentIndex Score
5
Cited by
6
References
5
Claims

Abstract

Pharmaceutical compositions of an erythromycin derivative combined with sulfisoxazole according to the structural formulas: ##STR1## where R is hydrogen, C1-C10 alkylcarbonyl or C1-C10 alkyl wherein the substituent is amino or cyano; R1 and R2 are independently hydrogen, hydroxyl or amino; and the pharmaceutical salts and esters thereof.

Claims

exact text as granted — not AI-modified
I claim: 
     
       1. A pharmaceutical composition containing an erythromycin derivative in combination with an acetylsulfisoxazole according to the structural formulas: ##STR3## wherein R is hydrogen, C1-C10 alkylcarbonyl, or substituted C1-C10 alkyl, wherein said substituent is amino or cyano; R 1  and R 2  are independently hydrogen, hydroxyl or amino; and pharmaceutical salts and esters thereof.   
     
     
       2. A pharmaceutical composition of a erythromycin derivative combined with acetylsulfisoxazole according to the structural formula: ##STR4## and the pharmaceutically acceptable salts, esters and metal complexes thereof, wherein R 1  is hydrogen,   C1-C10 alkylcarbonyl or unsubstituted or substituted   C1-C10 alkyl wherein said substituent is amino or cyano;   R 2  and R 3  are hydrogen;   R 2  and R 3  together are oxo;   R 4  is hydrogen or C1-C10 alkylcarbonyl;   R 5  and R 6  are independently hydrogen, hydroxy or amino;   R 5  and R 6  together are oxo or oximino;   R 7  and R 8  are independently hydrogen, C1-C10 alkyl or phenylsulfonyl;   R 9  is hydrogen, or C1-C10 alkylcarbony,   R 10  is hydrogen, and   R 11  is hydrogen or acetyl.   
     
     
       3. The composition of claim 1, wherein the erythromycin derivative has the structural formula: ##STR5## wherein R is methyl, R 1  is H and R 2  is OH. 
     
     
       4. The composition of claim 1, wherein the erythromycin derivative has the structural formula: ##STR6## wherein R is amino alkyl carbonyl, R 1  is H and R 2  is OH. 
     
     
       5. The composition of claim 1, wherein the erythromycin derivative has the structural formula: ##STR7## wherein R is cyano, R 1  is an amino group, and R 2  is H.

Join the waitlist — get patent alerts

Track US5641753A — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.